Alembic Pharma Q3 FY26 Profit Slips to Rs 133 Cr After One-Time Labour Code Provision, Revenue Up 11%
Mumbai: Alembic Pharmaceuticals Limited reported an 11 percent year-on-year increase in consolidated revenue from operations to Rs 1,876 crore for the third quarter ended December 31, 2025, supported by steady performance across domestic and international businesses. EBITDA for the quarter rose 14 percent to Rs 308 crore, with an EBITDA margin of 16 percent.
Profit before exceptional items and tax increased 15 percent year-on-year to Rs 205 crore. However, reported profit after tax stood at Rs 133 crore, impacted by a one-time provision of Rs 42 crore recognised towards employee benefits following changes under the new labour code.
Commenting on the performance, Alembic Pharmaceuticals Managing Director Pranav Amin said the company maintained strong operational momentum during the quarter, driven by disciplined execution and a continued focus on profitability. “We further strengthened our presence in Australia, Canada, Europe, the USA and other key markets, delivering an overall growth of 11 percent,” he said, adding that the company’s pre-R&D EBITDA margin remained healthy at 25 percent.
Amin noted that Alembic continued to invest around 9 percent of revenue in research and development to strengthen its pipeline for future growth. He also highlighted steady progress in the integration of Utility Therapeutics, with preparations underway for the launch of Pivya™ in the fourth quarter, which is expected to expand Alembic’s branded drugs footprint in the US market.
In India, the company’s branded formulations business recorded a 6 percent year-on-year growth to Rs 652 crore during the quarter, aided by strong traction in gynaecology, ophthalmology and animal healthcare segments. The anti-infective segment grew broadly in line with market trends, while four new products were successfully introduced during the quarter.
Alembic’s US generics business grew 6 percent year-on-year to Rs 553 crore, with two product launches during the quarter. The ex-US international generics business delivered robust growth of 36 percent to Rs 406 crore. During the quarter, the company received seven ANDA approvals, taking its cumulative ANDA approvals to 232.
The API business reported a marginal growth of 2 percent year-on-year, with quarterly revenue reaching Rs 264 crore.
For the nine months ended December 31, 2025, Alembic reported consolidated revenue from operations of Rs 5,497 crore, marking a 12 percent increase compared to the corresponding period last year.
The company has scheduled its earnings call for investors and analysts at 4:30 pm IST on February 5, 2026, during which the senior management will discuss the quarterly performance and future outlook.
Alembic Pharmaceuticals Limited, founded in 1907, is a vertically integrated, research-driven pharmaceutical company with a strong presence in branded generics in India and regulated generics markets globally. Its manufacturing and R&D facilities are approved by several global regulatory authorities, including the USFDA.
